Concepts (176)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tumor Suppressor Protein p53 | 3 | 2010 | 415 | 0.550 |
Why?
|
| Imidazoles | 3 | 2014 | 140 | 0.510 |
Why?
|
| Piperazines | 3 | 2017 | 283 | 0.500 |
Why?
|
| Interleukin-6 | 2 | 2006 | 264 | 0.450 |
Why?
|
| Folic Acid | 1 | 2014 | 63 | 0.450 |
Why?
|
| ras Proteins | 1 | 2014 | 130 | 0.430 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 3 | 2010 | 79 | 0.400 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2014 | 665 | 0.350 |
Why?
|
| Puromycin | 1 | 2009 | 10 | 0.330 |
Why?
|
| Intranuclear Inclusion Bodies | 1 | 2009 | 3 | 0.330 |
Why?
|
| Liver Neoplasms, Experimental | 2 | 2006 | 26 | 0.320 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2017 | 1131 | 0.320 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2009 | 108 | 0.320 |
Why?
|
| Cytoskeleton | 1 | 2010 | 195 | 0.310 |
Why?
|
| Reactive Oxygen Species | 3 | 2015 | 490 | 0.310 |
Why?
|
| Micronuclei, Chromosome-Defective | 1 | 2008 | 5 | 0.310 |
Why?
|
| Lactams, Macrocyclic | 1 | 2008 | 13 | 0.310 |
Why?
|
| Benzoquinones | 1 | 2008 | 26 | 0.310 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2009 | 115 | 0.310 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2008 | 47 | 0.300 |
Why?
|
| Mitosis | 1 | 2008 | 152 | 0.290 |
Why?
|
| Genetic Vectors | 1 | 2009 | 446 | 0.290 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2006 | 399 | 0.290 |
Why?
|
| Myocytes, Cardiac | 3 | 2015 | 314 | 0.280 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2009 | 290 | 0.280 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2017 | 586 | 0.280 |
Why?
|
| Cell Movement | 1 | 2010 | 787 | 0.270 |
Why?
|
| Cell Line, Tumor | 7 | 2016 | 2588 | 0.260 |
Why?
|
| Drug Implants | 1 | 2006 | 34 | 0.260 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2005 | 17 | 0.250 |
Why?
|
| Toxicity Tests | 2 | 2015 | 13 | 0.240 |
Why?
|
| Nuclear Proteins | 1 | 2009 | 728 | 0.230 |
Why?
|
| Cell Proliferation | 2 | 2014 | 1670 | 0.230 |
Why?
|
| Hepatocytes | 1 | 2005 | 122 | 0.230 |
Why?
|
| Colonic Neoplasms | 1 | 2008 | 572 | 0.220 |
Why?
|
| Induced Pluripotent Stem Cells | 2 | 2015 | 120 | 0.210 |
Why?
|
| Trans-Activators | 1 | 2005 | 443 | 0.200 |
Why?
|
| Heart Diseases | 2 | 2015 | 302 | 0.200 |
Why?
|
| Transcription Factors | 1 | 2009 | 1665 | 0.180 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2016 | 1284 | 0.160 |
Why?
|
| DNA-Binding Proteins | 1 | 2005 | 1243 | 0.160 |
Why?
|
| Genes, erbB-1 | 1 | 2017 | 16 | 0.150 |
Why?
|
| Midazolam | 1 | 2017 | 48 | 0.150 |
Why?
|
| Pyrrolidines | 1 | 2017 | 60 | 0.140 |
Why?
|
| Pyrazines | 1 | 2017 | 91 | 0.140 |
Why?
|
| Inflammatory Breast Neoplasms | 1 | 2016 | 4 | 0.130 |
Why?
|
| Piperidines | 1 | 2017 | 163 | 0.130 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2016 | 135 | 0.120 |
Why?
|
| Pyridazines | 1 | 2014 | 21 | 0.120 |
Why?
|
| High-Throughput Screening Assays | 1 | 2015 | 58 | 0.120 |
Why?
|
| Methylenetetrahydrofolate Dehydrogenase (NADP) | 1 | 2014 | 4 | 0.120 |
Why?
|
| Signal Transduction | 4 | 2016 | 3404 | 0.120 |
Why?
|
| B7-H1 Antigen | 1 | 2016 | 279 | 0.110 |
Why?
|
| Bone Morphogenetic Protein Receptors, Type II | 1 | 2013 | 14 | 0.110 |
Why?
|
| Antineoplastic Agents | 2 | 2015 | 2331 | 0.110 |
Why?
|
| Activins | 1 | 2013 | 26 | 0.110 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2014 | 165 | 0.110 |
Why?
|
| Cell Survival | 3 | 2015 | 983 | 0.100 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2014 | 486 | 0.100 |
Why?
|
| Neoplasm Invasiveness | 2 | 2013 | 569 | 0.100 |
Why?
|
| Receptors, Cell Surface | 1 | 2013 | 288 | 0.100 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2016 | 600 | 0.100 |
Why?
|
| G2 Phase | 2 | 2008 | 33 | 0.100 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2013 | 306 | 0.100 |
Why?
|
| Antigens, CD | 1 | 2013 | 466 | 0.100 |
Why?
|
| HCT116 Cells | 2 | 2008 | 156 | 0.090 |
Why?
|
| Genomics | 1 | 2016 | 778 | 0.090 |
Why?
|
| Stress Fibers | 1 | 2010 | 24 | 0.090 |
Why?
|
| Pseudopodia | 1 | 2010 | 37 | 0.080 |
Why?
|
| Focal Adhesions | 1 | 2010 | 70 | 0.080 |
Why?
|
| Promyelocytic Leukemia Protein | 1 | 2009 | 8 | 0.080 |
Why?
|
| SUMO-1 Protein | 1 | 2009 | 16 | 0.080 |
Why?
|
| Mutation | 3 | 2017 | 4169 | 0.080 |
Why?
|
| Cell Line | 2 | 2014 | 2495 | 0.080 |
Why?
|
| Rats | 2 | 2006 | 4048 | 0.080 |
Why?
|
| Polyploidy | 1 | 2008 | 18 | 0.080 |
Why?
|
| HT29 Cells | 1 | 2008 | 50 | 0.080 |
Why?
|
| Humans | 12 | 2017 | 90014 | 0.080 |
Why?
|
| Cell Differentiation | 1 | 2014 | 1533 | 0.070 |
Why?
|
| DNA Replication | 1 | 2008 | 171 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2017 | 1929 | 0.070 |
Why?
|
| Protein Folding | 1 | 2009 | 291 | 0.070 |
Why?
|
| Actins | 1 | 2010 | 462 | 0.070 |
Why?
|
| Cell Division | 1 | 2008 | 692 | 0.070 |
Why?
|
| Hexuronic Acids | 1 | 2006 | 10 | 0.070 |
Why?
|
| Glucuronic Acid | 1 | 2006 | 11 | 0.070 |
Why?
|
| Animals | 4 | 2014 | 27536 | 0.070 |
Why?
|
| Alginates | 1 | 2006 | 16 | 0.070 |
Why?
|
| Cricetulus | 1 | 2006 | 127 | 0.060 |
Why?
|
| CHO Cells | 1 | 2006 | 188 | 0.060 |
Why?
|
| Rats, Inbred ACI | 1 | 2005 | 25 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2005 | 70 | 0.060 |
Why?
|
| RNA, Neoplasm | 1 | 2005 | 88 | 0.060 |
Why?
|
| Cricetinae | 1 | 2006 | 558 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2006 | 374 | 0.060 |
Why?
|
| STAT3 Transcription Factor | 1 | 2005 | 86 | 0.060 |
Why?
|
| Drug Compounding | 1 | 2006 | 85 | 0.060 |
Why?
|
| Random Allocation | 1 | 2005 | 327 | 0.060 |
Why?
|
| Probability | 1 | 2005 | 351 | 0.060 |
Why?
|
| Transfection | 1 | 2006 | 909 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 885 | 0.050 |
Why?
|
| Prostatic Neoplasms | 1 | 2013 | 1747 | 0.050 |
Why?
|
| Enzyme Activation | 2 | 2013 | 696 | 0.050 |
Why?
|
| Oxidative Stress | 2 | 2015 | 458 | 0.050 |
Why?
|
| Disease Progression | 1 | 2006 | 1469 | 0.050 |
Why?
|
| Base Sequence | 1 | 2005 | 2329 | 0.050 |
Why?
|
| Molecular Sequence Data | 1 | 2005 | 3024 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2005 | 2018 | 0.040 |
Why?
|
| Liver Neoplasms | 1 | 2006 | 755 | 0.040 |
Why?
|
| Mice | 1 | 2014 | 11858 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2017 | 606 | 0.040 |
Why?
|
| Cells, Cultured | 2 | 2015 | 2887 | 0.040 |
Why?
|
| Male | 4 | 2017 | 42705 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2005 | 2395 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2015 | 2327 | 0.040 |
Why?
|
| Receptor, ErbB-3 | 1 | 2016 | 19 | 0.030 |
Why?
|
| Mutation Rate | 1 | 2016 | 49 | 0.030 |
Why?
|
| Time Factors | 2 | 2015 | 5361 | 0.030 |
Why?
|
| Troponin I | 1 | 2015 | 26 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 268 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2016 | 371 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 1169 | 0.030 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2016 | 189 | 0.030 |
Why?
|
| Troponin | 1 | 2014 | 24 | 0.030 |
Why?
|
| Mitochondria, Heart | 1 | 2014 | 50 | 0.030 |
Why?
|
| Molecular Structure | 1 | 2015 | 293 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2016 | 557 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2015 | 417 | 0.030 |
Why?
|
| Smad1 Protein | 1 | 2013 | 3 | 0.030 |
Why?
|
| Lipid Metabolism | 1 | 2015 | 201 | 0.030 |
Why?
|
| Activin Receptors, Type II | 1 | 2013 | 9 | 0.030 |
Why?
|
| Endoglin | 1 | 2013 | 21 | 0.030 |
Why?
|
| Cell Death | 1 | 2014 | 261 | 0.030 |
Why?
|
| ERG1 Potassium Channel | 1 | 2013 | 15 | 0.030 |
Why?
|
| Caspase 7 | 1 | 2013 | 15 | 0.030 |
Why?
|
| Ether-A-Go-Go Potassium Channels | 1 | 2013 | 27 | 0.030 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2013 | 86 | 0.030 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2013 | 88 | 0.030 |
Why?
|
| Neoplasms | 1 | 2008 | 3067 | 0.030 |
Why?
|
| Pluripotent Stem Cells | 1 | 2013 | 34 | 0.030 |
Why?
|
| Caspase 3 | 1 | 2013 | 162 | 0.030 |
Why?
|
| Actin Cytoskeleton | 1 | 2014 | 197 | 0.030 |
Why?
|
| Computational Biology | 1 | 2016 | 551 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 490 | 0.030 |
Why?
|
| Pyrazoles | 1 | 2013 | 150 | 0.020 |
Why?
|
| Patch-Clamp Techniques | 1 | 2013 | 397 | 0.020 |
Why?
|
| Pyrroles | 1 | 2013 | 172 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 283 | 0.020 |
Why?
|
| Heart Rate | 1 | 2014 | 498 | 0.020 |
Why?
|
| Quinazolines | 1 | 2013 | 212 | 0.020 |
Why?
|
| Ion Channels | 1 | 2013 | 246 | 0.020 |
Why?
|
| Lipids | 1 | 2013 | 275 | 0.020 |
Why?
|
| Indoles | 1 | 2013 | 301 | 0.020 |
Why?
|
| Pyridines | 1 | 2013 | 300 | 0.020 |
Why?
|
| Cholesterol | 1 | 2013 | 360 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2013 | 371 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2016 | 1452 | 0.020 |
Why?
|
| Protein Binding | 1 | 2013 | 1492 | 0.020 |
Why?
|
| RNA | 1 | 2013 | 583 | 0.020 |
Why?
|
| Cyclin B | 1 | 2008 | 18 | 0.020 |
Why?
|
| Models, Biological | 1 | 2016 | 1766 | 0.020 |
Why?
|
| Cyclin B1 | 1 | 2008 | 18 | 0.020 |
Why?
|
| Cyclin A | 1 | 2008 | 29 | 0.020 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2008 | 43 | 0.020 |
Why?
|
| CDC2 Protein Kinase | 1 | 2008 | 46 | 0.020 |
Why?
|
| G1 Phase | 1 | 2008 | 65 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 2770 | 0.020 |
Why?
|
| Biomarkers | 1 | 2015 | 1778 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 6787 | 0.020 |
Why?
|
| DNA Damage | 1 | 2008 | 374 | 0.020 |
Why?
|
| Female | 2 | 2017 | 46617 | 0.010 |
Why?
|
| DNA | 1 | 2008 | 1311 | 0.010 |
Why?
|
| Apoptosis | 1 | 2008 | 1718 | 0.010 |
Why?
|
| Aged | 1 | 2017 | 19272 | 0.010 |
Why?
|
| Middle Aged | 1 | 2017 | 26173 | 0.010 |
Why?
|
| Adult | 1 | 2017 | 26836 | 0.010 |
Why?
|